{"changeSha256":"d7c5bc8cc46660f0eddb9ad3a07280c6fe148dd6a7e009a78e7046304329251b","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Adlyxin and in Soliqua 100/33","before":"U.S. label record","field":"Status"},{"after":"A GLP-1 receptor agonist approved by FDA as Adlyxin, and in combination with insulin glargine as Soliqua 100/33, to improve blood-sugar control in adults with type 2 diabetes.","before":"A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.","field":"Profile summary"},{"after":"Large randomized trials described in the labels support these uses. In the ELIXA trial of 6,068 adults after a recent acute coronary syndrome, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.","before":"The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"Soliqua 100/33, Adlyxin","before":"Soliqua 100/33","field":"Related names"},{"after":"dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-adlyxin-label-2024, fda-drugs-bla208471-2016-07-27-6e0355642026","before":"dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-adlyxin-label-2024","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25]; U.S. Food and Drug Administration [sources: fda-drugs-bla208471-2016-07-27-6e0355642026, fda-adlyxin-label-2024]","before":"U.S. National Library of Medicine [sources: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25]","field":"Named organizations"},{"after":"name: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; aliases: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-adlyxin-label-2024, fda-drugs-bla208471-2016-07-27-6e0355642026; category: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; status: fda-drugs-bla208471-2016-07-27-6e0355642026, fda-adlyxin-label-2024, dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; summary: fda-adlyxin-label-2024, dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-drugs-bla208471-2016-07-27-6e0355642026; evidenceNote: fda-adlyxin-label-2024, dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25","before":"name: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; aliases: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; category: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; status: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; summary: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; evidenceNote: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/lixisenatide/versions/4/","version":4},"id":"profile:lixisenatide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers drawn from the Adlyxin and Soliqua 100/33 labels, and added the Drugs@FDA approval record for Adlyxin.","peptideSlugs":["lixisenatide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/lixisenatide/v3.json","sha256":"212079ddf6dab5ed66a4b6b4027d650c965fbdb3ab2fce6230b7b2d209112ecf"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/lixisenatide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-adlyxin-label-2024","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"ADLYXIN, revised November 2024: U.S. prescribing information","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208471s009lbl.pdf","verifiedAt":"2026-09-15"},{"id":"dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=25","verifiedAt":"2026-07-22"},{"id":"fda-drugs-bla208471-2016-07-27-6e0355642026","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application BLA208471 · original submission status AP · 2016-07-27 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA208471%22&limit=1","verifiedAt":"2026-08-14"}],"subject":{"slug":"lixisenatide","type":"profile"}}
